Liposomal pegylated forms of drugs in overcoming chemoresistance of advanced breast cancer

Breast cancer-related women mortality in the Ukraine accounts 18263 per year, or 22.2% of all cancer-related deaths. The existing breast cancer (BC) therapy suffers from various issues including recurrence and relapse. 30% BC patients develop chemoresistance throughout their treatment. Absence of available drugs targeting the chemoresistant BC cells, and the incapacity of drugs to be localized inside the tumor, developing alternative targeted therapies to deliver therapeutic agents is required. There is a need for development of suitable and effective drug delivery systems which can derive maximum benefits from a certain class of anti-cancer drug as well as reduce all the possible limitations amid the cancer therapy. Liposomes (nanostructured lipid carriers, solid lipid nanoparticles, micelles, and nanoemulsions) provide a variety of pharmaceutical benefits, including encapsulation of both hydrophobic and hydrophilic chemical moieties, improved solubility and stability, better bioenvironmental protection, modified drug release, and site-specific delivery of chemotherapeutics. PEGylation has been shown to increase the systemic residence duration of nanocarriers. The aim is emphasizing the direct administration of different medications to tumor cells for chemoresistant advanced breast cancer, fighting drug resistance. On the background of the chemotherapeutic agent’s administration, resistant BC cells acquire an aggressive phenotype with invasive and migratory abilities, but nanomedicine could overcome chemoresistance of conventional chemotherapy and reduce the toxicity by tumor targeting of nanocarriers. Many nanoplatforms are at various phases of pre-clinical and clinical study. However, there is still a need for pharmaceutical nanoplatform and nanocarriers system development and manufacturing unification.